Loading...
•
Dec 31, 2020
Regulus Therapeutics Q4 2020 Earnings Report
Regulus Therapeutics reported financial results for Q4 and year-end 2020 and provided a corporate update.
Key Takeaways
Regulus Therapeutics reported Q4 2020 revenue of $5.0 million, primarily from the achievement of an enrollment milestone and completion of material transfer to Sanofi. The company's cash and cash equivalents totaled $31.1 million as of December 31, 2020. Net loss for the quarter was $1.3 million, or $0.03 per share.
Completed enrollment in the first cohort of Phase 1b clinical trial of RGLS4326 for ADPKD.
Closed $19 million private financing.
Achieved $5 million milestone from Sanofi related to RG-012 enrollment.
Appointed Dr. Alice Huang to the Board of Directors.
Forward Guidance
Regulus expects net proceeds from the private placement, together with existing cash, will provide cash resources to fund planned activities through Q1 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...